Ibuprofen B. Braun (Ibuprofen)

Ibuprofen blocks the activity of cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for producing prostaglandins. By lowering prostaglandin levels, it diminishes pain signaling, reduces fever, and limits the inflammatory response at the site of tissue injury.

The appropriate dose of intravenous ibuprofen is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and renal or hepatic function. Dosage regimens are individualized and should follow the prescriber’s instructions.

Ibuprofen is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should be avoided in the third trimester and used only if the potential benefit justifies the risk. Limited data are available for breastfeeding; a healthcare professional should evaluate safety for mother and infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Both ibuprofen and ketorolac are injectable NSAIDs that provide analgesia and antipyresis. Ibuprofen generally has a slightly longer half‑life and a broader safety margin for gastrointestinal effects, while ketorolac is often considered more potent for short‑term postoperative pain but carries a higher risk of renal toxicity at comparable doses.

The product must be stored refrigerated at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration and administer only with aseptic technique in a clinical setting.

Ibuprofen B. Braun is given as an intravenous infusion, typically over 15–30 minutes, under the supervision of qualified healthcare personnel. The infusion rate and total daily dose are set by the prescriber, and the medication is administered using sterile equipment in a monitored environment.

Serious risks include gastrointestinal bleeding or ulceration, acute kidney injury, severe hypersensitivity reactions such as anaphylaxis, and rare cases of hepatic failure. Patients should be monitored for signs of bleeding, renal dysfunction, or allergic reactions during and after infusion.

Contraindications include known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulcer or bleeding, severe renal or hepatic impairment, third‑trimester pregnancy, and patients receiving certain anticoagulants without close monitoring. Clinicians should assess each patient’s medical history before prescribing.